Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
AdvanDx, a provider of molecular diagnostic tests for identifying pathogens that cause critical infections in hospitalized patients, announced the commercial launch of Gram-Negative QuickFISH BC, the third FDA-cleared test in its QuickFISH blood culture pathogen identification platform.
GeneDx announced the launch of a comprehensive suite of genetic tests for inherited cancer, including a 26-gene panel for breast and ovarian cancer that includes BRCA1 and BRCA2 and next-generation sequencing-based multi-gene panels for colorectal cancer, pancreatic cancer, and endometrial cancer.
Next-generation sequencing technologies have become faster and more efficient while library preparation remains a bottleneck. Laboratories require high-throughput, high-quality, stable, clinically relevant, and reproducible sample preparations. Solutions to these problems must not only solve time constraints but do so without the human errors associated with manual methods.
Myriad Genetics’ myRisk Hereditary Cancer is a multi-gene diagnostic test that provides increased sensitivity by analyzing 25 genes associated with eight major cancers, including breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric, and melanoma.
Each test report will include a genetic test result, a clinical risk report, and a health care management tool based on professional society guidelines, providing clear and actionable information to improve patient care regardless of whether the patient receives a positive or negative test result.
Thermo Fisher Scientific’s Peltier-cooled incubators with solid-state Peltier cooling are for biological and genomics laboratory researchers engaged in fruit fly and biochemical oxygen demand research.
Abbott will add a new FDA-cleared molecular diagnostic test for detection and differentiation of influenza A and B and respiratory syncytial virus to its infectious disease testing menu. The IMDx Flu A/B and RSV test developed by IntelligentMDx (IMDx) of Cambridge, Mass., is performed on Abbott’s m2000 molecular diagnostics system.
The Clinical and Laboratory Standards Institute has released an updated edition of its standard NBS01-A6 (replaces LA04-A5), “Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard-Sixth Edition.” This document contains new information and insight for personnel on the essentials of correctly collecting a high-quality specimen, handling the specimen after it has been collected, transporting it to the testing facility, and sorting the residual specimen that remains after laboratory testing.
Diagnostic BioSystems added a new chromogen to its color spectrum—PermaBlack/HRP. This HRP-based substrate/chromogen system produces a sharply contrasting ebony black stain, which serves as a useful tool in immunohistochemical and in situ hybridization staining procedures.
September 2013—Life Technologies and RainTree Oncology Services have entered into a collaborative agreement designed to further the advancement of personalized care for cancer patients.
Seegene has entered into a collaborative agreement with Eidia, the in vitro diagnostics subsidiary arm of Eisai Co., headquartered in Japan. Through this agreement, Eidia gains access to Seegene’s portfolio of Toce technology-based multiplex molecular diagnostic tests for the Japanese diagnostic test market.
